



Final Appraisal Recommendation

Advice No: 2114 – July 2014

Linagliptin/metformin (Jentaduet[®])
2.5 mg/850 mg and 2.5 mg/1,000 mg film-coated tablets

Submission by Boehringer Ingelheim Ltd/Eli Lilly & Co Ltd

Recommendation of AWMSG

Linagliptin/metformin (Jentaduet[®]) is recommended as an option for use within NHS Wales for the treatment of adult patients with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:

- in patients inadequately controlled on their maximally tolerated dose of metformin alone
- in combination with other medicinal products for the treatment of diabetes, including insulin, in patients inadequately controlled with metformin and these medicinal products
- in patients already being treated with the combination of linagliptin and metformin as separate tablets.

Additional note:

- This advice incorporates and replaces the existing AWMSG recommendation on linagliptin/metformin (Jentaduet[®]) as an option for use within NHS Wales for the treatment of adult patients with type 2 diabetes mellitus:
 - as an adjunct to diet and exercise to improve glycaemic control in adult patients inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of linagliptin and metformin; and
 - in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea (Advice number 1113, originally published May 2013).
- Please refer to the Summary of Product Characteristics for the full licensed indication.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference numbers 1681 and 2446), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.



This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	Boehringer Ingelheim Ltd/Eli Lilly & Co Ltd
Date of first issue	July 2014
Last reviewed	April 2019

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 2114:
Linagliptin/metformin (Jentadueto[®]) 2.5 mg/850 mg and 2.5 mg/1,000 mg film-coated tablets.
July 2014.